Login
$OBK
$53.79 +$0.00 (0.0%) After hours

Consolidated Balance Sheets

In millions of USD; shares in millions, except per-share amounts
Q3 FY2026
As of Sep 30, 2026
Q2 FY2026
As of Jun 30, 2026
Q1 FY2026
As of Mar 31, 2026
Q4 FY2025
As of Dec 31, 2025
Q3 FY2025
As of Sep 30, 2025
Q2 FY2025
As of Jun 30, 2025
Q1 FY2025
As of Mar 31, 2025
Q4 FY2024
As of Dec 31, 2024
Q3 FY2024
As of Sep 30, 2024
Q2 FY2024
As of Jun 30, 2024
Q1 FY2024
As of Mar 31, 2024
Q4 FY2023
As of Dec 31, 2023
Q3 FY2023
As of Sep 30, 2023
Q2 FY2023
As of Jun 30, 2023
Q1 FY2023
As of Mar 31, 2023
Q4 FY2022
As of Dec 31, 2022
Q3 FY2022
As of Sep 30, 2022
Q2 FY2022
As of Jun 30, 2022
Q1 FY2022
As of Mar 31, 2022
Q4 FY2021
As of Dec 31, 2021
Assets
Cash and due from banks
Interest-earning deposits in banks
Total cash and cash equivalents
Securities:
Available for sale
Held to maturity, net of allowance for credit losses of $34 and $41 at September 30, 2026, and December 31, 2025, respectively (fair value of $20,097 and $9,607 at September 30, 2026, and December 31, 2025, respectively)
Securities carried at fair value through income
Total securities
Non-marketable equity securities held in other financial institutions
Equity method investments
Loans held for sale
Loans, net of allowance for credit losses of $98,378 and $96,782 at September 30, 2026, and December 31, 2025, respectively
Premises and equipment, net
Mortgage servicing rights (“MSR”)
Cash surrender value of bank-owned life insurance
Goodwill
Other intangible assets, net
Accrued interest receivable and other assets
Total assets
Liabilities and Shareholders’ Equity
Noninterest-bearing deposits
Interest-bearing deposits
Time deposits
Total deposits
Federal Home Loan Bank (“FHLB”) advances, repurchase agreements and other borrowings
Subordinated indebtedness, net
Accrued expenses and other liabilities
Total liabilities
Commitments and contingencies - See Note 19 — Commitments and Contingencies
Shareholders’ equity:
Preferred stock, no par value, 2,000,000 shares authorized
Common stock ($5.00 par value; 50,000,000 shares authorized; 30,602,833 and 30,952,428 shares issued and outstanding at September 30, 2026, and December 31, 2025, respectively)
Additional paid‑in capital
Retained earnings
Accumulated other comprehensive loss
Total shareholders’ equity
Total liabilities and shareholders’ equity
Common stock, shares issued (in shares)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support